Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma

A patient with relapsed B cell non-Hodgkin lymphoma (NHL) infiltrating the Central nervous system (CNS) and resistant to chemotherapy was treated with intrathecal Rituximab (IT RTX), administered weekly for eight weeks at increasing doses, from 10 to 40 mg. After the second administration the patien...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2007-01, Vol.81 (2), p.197-199
Main Authors: Antonini, Giovanni, Cox, Maria Cristina, Montefusco, Enrico, Ferrari, Antonella, Conte, Esmeralda, Morino, Stefania, Latino, Pamela, Trasimeni, Guido, Monarca, Bruno
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 - immunology
Antineoplastic Agents - therapeutic use
Female
Humans
Injections, Spinal
Lymphoma, B-Cell - immunology
Lymphoma, B-Cell - therapy
Lymphoma, Large B-Cell, Diffuse - immunology
Lymphoma, Large B-Cell, Diffuse - therapy
Meningeal Neoplasms - immunology
Meningeal Neoplasms - therapy
Rituximab
Salvage Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A patient with relapsed B cell non-Hodgkin lymphoma (NHL) infiltrating the Central nervous system (CNS) and resistant to chemotherapy was treated with intrathecal Rituximab (IT RTX), administered weekly for eight weeks at increasing doses, from 10 to 40 mg. After the second administration the patient showed significant clinical improvement and Cerebro spinal fluid (CSF) clearance of lymphomatous cells. A MRI scan performed after 30 days from the start of therapy showed full regression of lymphomatous infiltration. This report confirms the efficacy and safety of IT RTX in the treatment of CNS B-cell NHL.
ISSN:0167-594X
1573-7373
DOI:10.1007/s11060-006-9217-y